A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy

Thumbnail image of item number 1 in: 'A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy'.
Thumbnail image of item number 2 in: 'A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy'.
Thumbnail image of item number 3 in: 'A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy'.
Thumbnail image of item number 4 in: 'A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy'.
Showing 1-4 of 17 pages in this article.

PDF Version Also Available for Download.

Description

This article gives an overview of the discovery of small-molecule bioprecursor prodrugs carrying the para-quinol scaffold on the steroidal A-ring that are preferentially metabolized in the CNS to the corresponding estrogens. Selected examples are shown to illustrate that, independently of the route of administrations and duration of treatments, these agents produce high concentration of estrogens only in the CNS without peripheral hormonal liability. 10β,17β-Dihydroxyestra-1,4-dien-3-one (DHED) has been the best-studied representative of this novel type of prodrugs for brain and retina health. Specific applications in preclinical animal models of centrally-regulated and estrogen-responsive human diseases, including neurodegeneration, menopausal symptoms, cognitive decline and … continued below

Physical Description

17 p.

Creation Information

Prokai-Tatrai, Katalin & Prókai, László, 1958- November 19, 2019.

Context

This article is part of the collection entitled: UNT Scholarly Works and was provided by the UNT Health Science Center to the UNT Digital Library, a digital repository hosted by the UNT Libraries. It has been viewed 29 times. More information about this article can be viewed below.

Who

People and organizations associated with either the creation of this article or its content.

Authors

Publisher

Provided By

UNT Health Science Center

UNT Health Science Center is one of the nation's premier graduate academic medical centers, with five schools that specialize in patient-centered education, research, and health care: Texas College of Osteopathic Medicine, Graduate School of Biomedical Sciences, School of Public Health, School of Health Professions, and UNT System College of Pharmacy.

About | Browse this Partner

Contact Us

Corrections Questions

What

Descriptive information to help identify this article. Follow the links below to find similar items on the Digital Library.

Degree Information

Description

This article gives an overview of the discovery of small-molecule bioprecursor prodrugs carrying the para-quinol scaffold on the steroidal A-ring that are preferentially metabolized in the CNS to the corresponding estrogens. Selected examples are shown to illustrate that, independently of the route of administrations and duration of treatments, these agents produce high concentration of estrogens only in the CNS without peripheral hormonal liability. 10β,17β-Dihydroxyestra-1,4-dien-3-one (DHED) has been the best-studied representative of this novel type of prodrugs for brain and retina health. Specific applications in preclinical animal models of centrally-regulated and estrogen-responsive human diseases, including neurodegeneration, menopausal symptoms, cognitive decline and depression, are discussed to demonstrate the translational potential of their prodrug approach for CNS-selective and gender-independent estrogen therapy with inherent therapeutic safety.

Physical Description

17 p.

Notes

Abstract: Beneficial effects of estrogens in the central nervous system (CNS) results from the synergistic combination of their well-orchestrated genomic and non-genomic actions, making them potential broad-spectrum neurotherapeutic agents. However, owing to unwanted peripheral hormonal burdens by any currently known non-invasive drug administrations, the development of estrogens as safe pharmacotherapeutic modalities cannot be realized until they are confined specifically and selectively to the site of action. We have developed small-molecule bioprecursor prodrugs carrying the para-quinol scaffold on the steroidal A-ring that are preferentially metabolized in the CNS to the corresponding estrogens. Here, we give an overview of our discovery of these prodrugs. Selected examples are shown to illustrate that, independently of the route of administrations and duration of treatments, these agents produce high concentration of estrogens only in the CNS without peripheral hormonal liability. 10β,17β-Dihydroxyestra-1,4-dien-3-one (DHED) has been the best-studied representative of this novel type of prodrugs for brain and retina health. Specific applications in preclinical animal models of centrally-regulated and estrogen-responsive human diseases, including neurodegeneration, menopausal symptoms, cognitive decline and depression, are discussed to demonstrate the translational potential of our prodrug approach for CNS-selective and gender-independent estrogen therapy with inherent therapeutic safety.

Source

  • Molecules, 24(22), Multidisciplinary Digital Publishing Institute, November 2019

Language

Item Type

Identifier

Unique identifying numbers for this article in the Digital Library or other systems.

Publication Information

  • Publication Title: Molecules
  • Volume: 24
  • Issue: 22
  • Peer Reviewed: Yes

Collections

This article is part of the following collection of related materials.

UNT Scholarly Works

Materials from the UNT community's research, creative, and scholarly activities and UNT's Open Access Repository. Access to some items in this collection may be restricted.

About | Browse this Collection

What responsibilities do I have when using this article?

Digital Files

When

Dates and time periods associated with this article.

Creation Date

  • November 19, 2019

Added to The UNT Digital Library

  • May 11, 2020, 3:41 p.m.

Description Last Updated

  • Nov. 9, 2023, 11:54 a.m.

Usage Statistics

When was this article last used?

Yesterday: 0
Past 30 days: 0
Total Uses: 29
More Statistics

Interact With This Article

Here are some suggestions for what to do next.

Start Reading

Thumbnail image of item number 1 in: 'A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy'.
Thumbnail image of item number 2 in: 'A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy'.
Thumbnail image of item number 3 in: 'A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy'.
Thumbnail image of item number 4 in: 'A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy'.

PDF Version Also Available for Download.

Citations, Rights, Re-Use

International Image Interoperability Framework

IIF Logo

We support the IIIF Presentation API

Links for Robots

Helpful links in machine-readable formats.

Archival Resource Key (ARK)

International Image Interoperability Framework (IIIF)

Metadata Formats

Images

URLs

Stats

Prokai-Tatrai, Katalin & Prókai, László, 1958-. A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy, article, November 19, 2019; [Basel, Switzerland]. (https://digital.library.unt.edu/ark:/67531/metadc1638221/: accessed December 3, 2023), University of North Texas Libraries, UNT Digital Library, https://digital.library.unt.edu; crediting UNT Health Science Center.

Back to Top of Screen